Pharma

Pharma

New digital health player HealthHero launches with Fernarzt buy
Pharma

New digital health player HealthHero launches with Fernarzt buy

There’s a new kid on the block in digital health – called HealthHero – with aspirations to become the biggest company in the European market.The new company officially comes into being today with the acquisition of Berlin-based telemedicine company Fernarzt, which was set up in 2017 and is already offering thousands of online consultations each month in Germany.Ranjan SinghHealthHero has been launched by Ranjan Singh, managing director of digital health for London based investment house MARCOL, which has bankrolled the Fernarzt acquisition.Singh will serve as CEO of the group alongside his role as chairman of Medical Consultations, a 20-year-old telemedicine company based in the UK that is at the heart of the HealthHero group. He was named CEO of the UK company in February.“Fernarzt is a g...
Roche’s Rozlytrek Receives EC’s Conditional Marketing Authorization for NTRK Fusion-Positive Solid Tumors and ROS1-Positive Advanced NSCLC
Pharma

Roche’s Rozlytrek Receives EC’s Conditional Marketing Authorization for NTRK Fusion-Positive Solid Tumors and ROS1-Positive Advanced NSCLC

Shots: The approval is based on integrated analysis including data from 74 people with LA/ m-NTRK fusion-positive solid tumors (14 tumor types) & 161 people with ROS1+ NSCLC of the pivotal P-II STARTRK-2, P-I STARTRK-1 and P-I ALKA-372-001 trials, and data from the P-I/II STARTRK-NG study in pediatric patientsResult: in NTRK fusion+ solid tumors, ORR (63.5%); mDoR (12.9mos.); In ROS1+ advanced NSCLC, shrank tumors in 73.4% of patients; DoR of 16.5mos. (14.6-28.6mos.); ORR (67.1%); in patients with CNS metastases with an intracranial ORR (62.5% & 77.8%); In pediatric patients, Rozlytrek shrank tumors in all children and adolescents who had NTRK gene fusions with two achieving a CRRozlytrek (entrectinib, qd) is a tumor-agnostic treatment for LA/m-solid tumors harbor...
Sanofi and GSK Receive $2.1B from the US Government to Supply 100M Doses of COVID-19 Vaccine
Pharma

Sanofi and GSK Receive $2.1B from the US Government to Supply 100M Doses of COVID-19 Vaccine

Shots: The US government will provide ~$2.1B to support the development of the vaccine, including clinical trials with some amount to be used for ramping up the manufacturing and delivery of an initial 100M dose of the vaccineThe US government has an option to supply an additional 500M dose and helps the government’s Operation Warp Speed goals for providing millions of doses of a safe and effective COVID-19 vaccineAdditionally, the companies are in discussion with the EC for the supply of up to 300M doses of a COVID-19 vaccine. Both the companies are committed to making their COVID-19 vaccine affordable and available globallyClick here, Click here ­to­ read full press release/ article | Ref: GSK, GSK | Image: WorldPharma Today Related News: Sanofi and GSK Sign an Ag...
COVID-19 and obesity is a lethal mix
Pharma

COVID-19 and obesity is a lethal mix

QUICK READ: Obesity is associated with a higher risk of developing severe symptoms and complications of coronavirus disease, independent of other illnesses, such as cardiovascular disease. So why haven’t we acted? Data seems to suggest that people with obesity are more likely to become severely ill due to COVID-19, the disease caused by the novel coronavirus. According to the US National National Library of Health, “obesity is an independent risk and prognostic factor for the disease severity and the requirement of advanced medical care in COVID-19. This systematic review highlights a particularly vulnerable group – obese, and emphasizes on the importance of treatment aggression and disease prevention in this population group”. Bill Maher said what we don’t want to hear “Th...
BCG shots could slow down Covid-19 spread in first thirty days, says study
Pharma

BCG shots could slow down Covid-19 spread in first thirty days, says study

(This story originally appeared in on Aug 02, 2020)MUMBAI: The debate over the anti-tuberculosis vaccine’s ability to protect against Covid-19 got a fresh lease with an American research paper stating that the BCG ‘slows down’ the infection’s spread within the community—at least in the first 30 days. The paper published in Science Advances, a peer-reviewed medical journal brought out by the American Association for the Advancement of Science, said that countries with mandatory Bacillus Calmette-Guérin (BCG) vaccination showed “slower infection and death rates” during the first 30 days of the Covid-19 outbreak in their country. The researchers estimated only 468 people are likely to have died from Covid-19 in the US as of March 29—which is 19% of the actual figure of 2,467 deaths by that d...
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
Pharma

The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients healthy during this pandemic and after. (more…)
Payers subject 80% of new RA and MS patients to utilization management restrictions
Pharma

Payers subject 80% of new RA and MS patients to utilization management restrictions

A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine encountered a utilization management restriction. Of those patients, 3 out of 10 were unable to gain approval from their commercial market health plan to start new treatments their doctors prescribed for them within 30 days. (more…)
Medicare’s 55th anniversary: Celebrating the success of Part D
Pharma

Medicare’s 55th anniversary: Celebrating the success of Part D

Today, we are excited to bring you a special edition of our Medicare Catalyst series in honor of Medicare’s 55th anniversary. On this date in 1965, President Lyndon B. Johnson signed into law legislation that established the Medicare and Medicaid programs. To celebrate this milestone, let’s take a closer look at the success of Medicare’s prescription drug benefit, also known as Part D, over the years.   (more…)
New data show commercially insured patients face increasingly high cost sharing for brand medicines
Pharma

New data show commercially insured patients face increasingly high cost sharing for brand medicines

New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy areas and found that anywhere from 44% to 95% of patients’ total out-of-pocket spending for brand medicines in 2019 was due to deductibles and coinsurance. Compared to patients who only paid copays for brand medicines, patients with deductibles or coinsurance had significantly higher annual out-of-pocket spending across all seven therapeutic areas. In fact, for patients with complex conditions, like cancer and HIV, spending was as much as 25 to 30 times higher. (more…)
Coronavirus Challenges in Primates, Compared
Pharma

Coronavirus Challenges in Primates, Compared

We have a sudden influx over the last few days of preclinical rhesus challenge studies with various coronavirus vaccines, and it’s only natural to try to compare them. I have worked up a table with all four of the current results and the previously reported SinoVac inactivated virus vaccine, whose rhesus challenge numbers were officially published earlier this month. This is the closest to Phase II human data that we’re going to have until later in the summer, so let’s see what we can make of it! Here is the Oxford/AstraZeneca vaccine, ChAdOx1, which is (as many have had the chance to memorize by now) a chimpanzee adenovirus repurposed with genetic material from the coronavirus Spike protein. This is the final published version of a preprint that came out earlier this year, whose re...